Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Apixaban is an oral direct inhibitor of factor Xa (activated factor X) with actions and uses similar to those of rivaroxaban.
It is indicated in the prevention and treatment of thromboembolism.
Administered orally twice daily.
It is excreted in human milk in a small amount, but it could be clinically significant (Zhao 2020).
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable (Daei 2021, Zhao 2020, Cohen 2016, Bates 2012), especially during the neonatal period and in cases of prematurity.